<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Panitumumab, a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is used as monotherapy for chemorefractory <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) in patients with <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicities</z:e> are the most common adverse events associated with EGFR inhibitors, the differences in efficacy and safety between pre-emptive and reactive skin treatment according to KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> status has not been reported </plain></SENT>
<SENT sid="2" pm="."><plain>PATIENTS AND METHODS: Eligible patients had mCRC with disease progression or unacceptable toxicity with first-line treatment containing fluoropyrimidine and <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi>-based chemotherapy Â± bevacizumab </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were randomized 1:1 to pre-emptive or reactive skin treatment (after <z:e sem="disease" ids="C1167791" disease_type="Disease or Syndrome" abbrv="">skin toxicity</z:e> developed) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received either panitumumab 6 mg/kg + FOLFIRI every 2 weeks or panitumumab 9 mg/kg + irinotecan every 3 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>Key study endpoints included overall response rate (ORR), overall survival, progression-free survival (PFS), and safety according to KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> status </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Eighty-seven (92%) of 95 enrolled patients had evaluable KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> status: 49 (56%) patients with WT and 38 (44%) patients with mutant (MT) KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The ORR was 16% and 8% for patients with WT and MT KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Median PFS was 5.5 and 3.3 months for patients with WT and MT KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, respectively </plain></SENT>
<SENT sid="9" pm="."><plain>The most commonly observed adverse events by KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> status included <z:hpo ids='HP_0000964'>dermatitis</z:hpo> acneiform and <z:hpo ids='HP_0000989'>pruritus</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: Panitumumab in combination with irinotecan-based chemotherapy has an acceptable toxicity profile in second-line therapy for mCRC </plain></SENT>
<SENT sid="11" pm="."><plain>Numerical differences trending in favor of the patients with WT KRAS <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were observed for most efficacy endpoints </plain></SENT>
</text></document>